{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:33:58Z","timestamp":1789032838860,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.cgh.2015.12.028","type":"journal-article","created":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T16:30:15Z","timestamp":1451579415000},"page":"836-842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis"],"prefix":"10.1016","volume":"14","author":[{"given":"Eduard Cornelis","family":"Verschuren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonsus Johannes","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Wonders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob Michel","family":"Slangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foke","family":"van Delft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"van Bodegraven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra","family":"Neefjes-Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanne Klaas","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2015.12.028_bib1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.cgh.2015.12.028_bib2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","article-title":"Principles and use of anti-CTLA4 antibody in human cancer immunotherapy","volume":"18","author":"Peggs","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cgh.2015.12.028_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2015.12.028_bib4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2015.12.028_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cgh.2015.12.028_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"van den Eertwegh","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cgh.2015.12.028_bib7","first-page":"825","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.cgh.2015.12.028_bib8","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cgh.2015.12.028_bib9","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cgh.2015.12.028_bib10","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cgh.2015.12.028_bib11","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1007\/s10620-008-0641-z","article-title":"Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab","volume":"54","author":"Johnston","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2015.12.028_bib12","first-page":"321","article-title":"Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis","volume":"24","author":"Minor","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.cgh.2015.12.028_bib13","unstructured":"World Health Organization. Diarrhoea. World Health Organization, 2014. Available at: http:\/\/www.who.int\/topics\/diarrhoea\/en\/. Accessed April 1, 2014."},{"key":"10.1016\/j.cgh.2015.12.028_bib14","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0","year":"2010"},{"key":"10.1016\/j.cgh.2015.12.028_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00004836-198804000-00013","article-title":"Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis","volume":"10","author":"van der Heide","year":"1988","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2015.12.028_bib16","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.crohns.2014.08.002","article-title":"Ipilimumab in a patient with known Crohn's disease: to give or not to give?","volume":"8","author":"Gielisse","year":"2014","journal-title":"Journal of Crohn's & colitis"},{"key":"10.1016\/j.cgh.2015.12.028_bib17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/MCG.0b013e31828f1d51","article-title":"Ipilimumab-induced perforating colitis","volume":"47","author":"Mitchell","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356515017127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356515017127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:08:28Z","timestamp":1748012908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356515017127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1542356515017127"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2015.12.028","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2015.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute","name":"copyright","label":"Copyright"}]}}